|
|
Volumn 102, Issue 10, 2010, Pages 675-677
|
|
Integrins as target: first phase III trial launches, but questions remain.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
CILENGITIDE;
INTEGRIN;
MONOCLONAL ANTIBODY;
SNAKE VENOM;
VOLOCIXIMAB;
ANIMAL;
BRAIN TUMOR;
CHEMICALLY INDUCED DISORDER;
DOSE RESPONSE;
DRUG ADMINISTRATION;
DRUG EFFECT;
GLIOBLASTOMA;
HUMAN;
METABOLISM;
NEOPLASM;
NOTE;
PHASE 3 CLINICAL TRIAL;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BRAIN NEOPLASMS;
CLINICAL TRIALS, PHASE III AS TOPIC;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
GLIOBLASTOMA;
HUMANS;
INTEGRINS;
NEOPLASMS;
SNAKE VENOMS;
|
|
EID: 77952986190
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djq186 Document Type: Note |
|
Times cited : (39)
|
|
References (0)
|
